Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: In some aspects, the techniques described herein relate to a method including: aggregating data for use in an interoperable P2P application; transferring funds from a user's account associated with a first disparate P2P funding application to fund an account associated with the interoperable P2P application; transferring the funds from the account associated with the interoperable P2P application to an account associated with a second disparate P2P application; initiating a transfer of the funds from the user's account associated with a second disparate P2P application to a colleague's account associated with the second disparate P2P application; and recording transactions carried out by the interoperable P2P application in a ledger system associated with the interoperable P2P application.

Abstract: The present disclosure provides chimeric antigen receptors (CARs), particularly CARs that have adaptable receptor specificity (arCARs). Also provided are polypeptides of the CARs and other related molecules, polynucleotides, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.

Abstract: Provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a polyethylene glycol (PEG) receptors and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.

Abstract: Provided are polynucleotides encoding inactivated cell surface receptors. Also provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a chimeric antigen receptor (CAR) and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.

Abstract: An implement analyzing device that is sized for receiving, more than one fluid retainer cartridge assembly is disclosed. The implement analyzing device includes a support member, a housing, a cartridge receiver, at least one cartridge heater, an Imaging, device and an implement analyzing device integrated circuit. The cartridge receiver is disposed within a cavity in the implement analyzing device and defines at least one cartridge viewing window. At least one cartridge heater disposed within the cavity and connected to the cartridge receiver. The imaging device is disposed within the cavity and arranged opposite the at least one cartridge viewing window. The implement analyzing device integrated circuit is communicatively coupled to the at least one cartridge heater and the imaging device.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: Provided are polynucleotides encoding inactivated cell surface receptors. Also provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a chimeric antigen receptor (CAR) and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.

Abstract: The present invention describes systems and methods for providing a resilient bidirectional charging infrastructure, including a plurality of smart poles connected in a circuit and a processor configured to cause the at least one of the plurality of smart poles to receive electricity from an electric vehicle based on an actual or predicted loss of electricity within the circuit. The plurality of smart poles is configured to provide at least part of a powered network, such as a 5G network, and at least one of the plurality of smart poles has an interface for receiving electricity from an electric vehicle.

Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: The present disclosure provides compositions and methods for use in genome engineering of induced pluripotent stem cells (iPSCs). Specifically, the methods and compositions described are useful for introducing transgenes into iPSCs such as pluripotent hematopoietic stem cells and/or progenitor cells (HSC/PC) using an CRISPR nuclease-based system (e.g., MAD7 nuclease-based system) and preparing immune-effector cells derived from the iPSCs.

Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: The present disclosure provides chimeric antigen receptors (CARs), particularly CARs that have adaptable receptor specificity (arCARs). Also provided are polypeptides of the CARs and other related molecules, polynucleotides, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.

Abstract: Provided are polynucleotides encoding inactivated cell surface receptors. Also provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a chimeric antigen receptor (CAR) and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.

Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: An implement analyzing device that is sized for receiving more than one fluid retainer cartridge assembly is disclosed. The implement analyzing device includes a support member, a housing, a cartridge receiver, at least one cartridge heater, an imaging device and an implement analyzing device integrated circuit. The cartridge receiver is disposed within a cavity in the implement analyzing device and defines at least one cartridge viewing window. At least one cartridge heater disposed within the cavity and connected to the cartridge receiver. The imaging device is disposed within the cavity and arranged opposite the at least one cartridge viewing window. The implement analyzing device integrated circuit is communicatively coupled to the at least one cartridge heater and the imaging device.

Abstract: Monoclonal anti-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies. The antibodies of the invention may also be used to quantify tau in biological samples.

Abstract: An implement analyzing device that is sized for receiving more than one fluid retainer cartridge assembly is disclosed. The implement analyzing device includes a support member, a housing, a cartridge receiver, at least one cartridge heater, an imaging device and an implement analyzing device integrated circuit. The cartridge receiver is disposed within a cavity in the implement analyzing device and defines at least one cartridge viewing window. At least one cartridge heater disposed within the cavity and connected to the cartridge receiver. The imaging device is disposed within the cavity and arranged opposite the at least one cartridge viewing window. The implement analyzing device integrated circuit is communicatively coupled to the at least one cartridge heater and the imaging device.

Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.